Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala.
Division of Vascular Surgery and Endovascular Therapy, University of Alabama at Birmingham, Birmingham, Ala.
J Vasc Surg. 2021 Jun;73(6):1991-1997.e3. doi: 10.1016/j.jvs.2020.11.039. Epub 2020 Dec 16.
Thoracofemoral bypass (TFB) has been used infrequently but is an alternative for select patients with aortoiliac occlusive disease. Limited data are available in the reported data regarding TFB, with all studies small, single-center series. We aimed to describe the perioperative and long-term survival, patency, and rate of major perioperative complications after TFB in a large national registry.
The Vascular Quality Initiative suprainguinal bypass module was used to identify patients who had undergone TFB for occlusive disease from 2009 to 2019. A descriptive analysis was performed to provide the rates of survival, patency, major complications, and freedom from major amputation in the perioperative period and at 1 year of follow-up. Major complications were compared by procedure indication, with categorical variables analyzed using χ tests and continuous variables using analysis of variance. Kaplan-Meier curve analysis was used to estimate survival at the 1- and 5-year follow-up intervals and freedom from major amputation at 1 year.
A total of 154 TFB procedures were identified. Of the 154 patients, 59 (38.3%) had undergone previous inflow bypass and 22 (14.2%) had undergone previous leg bypass. The procedure indications included claudication (n = 66; 42.9%), rest pain (n = 59; 38.3%), tissue loss (n = 19; 12.3%), and acute limb ischemia (n = 10; 6.5%). Major complications (eg, wound infection, respiratory, major stroke, new dialysis, cardiac, embolic, major amputation, occlusion) occurred in 31.2% of the cohort. When examined by indication, the acute limb ischemia and claudication cohorts had an increased rate of major complications (acute limb ischemia, 60.0%; claudication, 34.8%; critical limb ischemia, 24.4%; P = .05). The survival rate at 30 days was 95.5%, with a Kaplan-Meier estimated 1-year survival rate of 92.7% ± 2.2%. Primary patency at discharge from the index hospitalization was 92.9% and 89.0% at 1 year. Postoperative major amputation was required for 1 patient during the index hospitalization, for a Kaplan-Meier estimated freedom from major amputation at 1 year of 97.1% ± 2.2%. Two patients developed in-hospital bypass occlusion and three patients developed occlusion within 1 year, for an overall freedom from occlusion rate of 96.8% at 1 year.
TFB is associated with a high rate of perioperative major complications; however, the long-term survival and patency after TFB remained acceptable when performed for limb salvage. The high perioperative complication rates of TFB procedures performed for claudication suggest TFB should be used rarely in this population. These data can be used to counsel patients and aid in decision making before operative intervention.
胸股旁路(TFB)的应用虽不常见,但对于特定的主髂动脉闭塞性疾病患者来说,它是一种替代治疗方法。在现有的报告数据中,关于 TFB 的数据有限,所有研究均为小型单中心系列研究。我们旨在通过大型国家登记处,描述 TFB 治疗闭塞性疾病患者的围手术期和长期生存率、通畅率和主要围手术期并发症的发生率。
利用血管质量倡议(Vascular Quality Initiative)的腹主动脉旁路模块,确定 2009 年至 2019 年间接受 TFB 治疗的主髂动脉闭塞性疾病患者。进行描述性分析,提供围手术期和 1 年随访期间的生存率、通畅率、主要并发症和主要截肢的无截肢率。主要并发症通过手术适应证进行比较,分类变量采用卡方检验进行分析,连续变量采用方差分析进行分析。Kaplan-Meier 曲线分析用于估计 1 年和 5 年随访间隔的生存率和 1 年的无主要截肢率。
共确定了 154 例 TFB 手术。在这 154 例患者中,59 例(38.3%)之前进行过入流旁路手术,22 例(14.2%)之前进行过腿部旁路手术。手术适应证包括跛行(n=66;42.9%)、静息痛(n=59;38.3%)、组织缺失(n=19;12.3%)和急性肢体缺血(n=10;6.5%)。31.2%的患者发生了主要并发症(如伤口感染、呼吸、大中风、新透析、心脏、栓塞、大截肢、闭塞)。当按适应证检查时,急性肢体缺血和跛行组的主要并发症发生率较高(急性肢体缺血组为 60.0%;跛行组为 34.8%;严重肢体缺血组为 24.4%;P=0.05)。术后 30 天的生存率为 95.5%,Kaplan-Meier 估计 1 年生存率为 92.7%±2.2%。出院时的初始通畅率为 92.9%,1 年时为 89.0%。1 例患者在住院期间需要进行术后大截肢,Kaplan-Meier 估计 1 年的无大截肢率为 97.1%±2.2%。2 例患者在住院期间发生旁路再闭塞,3 例患者在 1 年内发生再闭塞,1 年时总通畅率为 96.8%。
TFB 与较高的围手术期主要并发症发生率相关;然而,当进行保肢治疗时,TFB 的长期生存率和通畅率仍然可以接受。对于因跛行而进行的 TFB 手术,其高围手术期并发症发生率表明 TFB 在该人群中很少使用。这些数据可以用于在手术干预前为患者提供咨询并辅助决策。